European Commission approves Actavis’ pending acquisition of Allergan

The European Commission has granted clearance for Actavis’ pending acquisition of Allergan, the two companies announced today.The clearance fulfilled the final regulatory condition necessary to close the pending acquisition, which is expected to be effective on or around March 17 and remains subject to customary closing conditions, according to a press release.